Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-01-24
2001-10-09
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S207000
Reexamination Certificate
active
06300354
ABSTRACT:
The invention relates to novel N-substituted azabicycloheptane derivatives, their preparation and use for controlling diseases. Exo-6-phenyl-3-azabicyclo[3.2.0]heptane derivatives have interesting properties as potential neuroleptics (WO 94/00458, WO 95/15312). In this connection, the observed high affinities for D
4
and 5-HT
2
receptors are particularly important.
The most interesting substance from the above classes of compounds with high D
4
/5-HT
2A
affinity and good selectivity versus D
2
is (+)-(1S,5R,6S)-exo-3-[2-[6-(4-fluorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-1H,3H-quinazoline-2,4-dione (=substance A), which represents a potential neuroleptic. However, there is an upper limit to the dosage of substance A owing to the prolongations occurring in the QT interval in the cardiac [sic] ECG.
Substances with better properties have now been found.
The invention relates to N-substituted 3-azabicyclo-[3.2.0]heptane derivatives of the formula I:
in which
R
1
is fluorine or chlorine,
R
2
and R
3
are hydrogen or C
1
-C
3
-alkyl, and
R
4
is chlorine, methyl, nitro or amino,
and the salts thereof with physiologically tolerated acids.
Preferred compounds are those in which
R
1
is chlorine, preferably in the p position,
R
2
is hydrogen or methyl,
R
3
is hydrogen or methyl and
R
4
is hydrogen.
The following compounds should be mentioned as particularly preferred:
(+)-(1S,5R,6S)-exo-2-[2-[6-(4-chlorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-3,3-dimethyl-2,3-dihydro-1,2-benzisothiazole 1, 1-dioxide,
(+)-(1S,5R,6S)-exo-2-[2-[6-(4-chlorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide, and
(+)-(1S,5R,6S)-exo-2-[2-[6-(4-fluorophenyl)-3-azabicyclo-[3.2.0]-heptan-3-yl]-ethyl]-2,3-dihydro-1,2 -benzisothiazole-1,1-dioxide.
The compounds of the formula I according to the invention can be prepared by reacting a compound of the formula II:
in which R
2
, R
3
and R
4
have the abovementioned meanings, and Nu is a nucleofugic leaving group, with a 3-azabicyclo-[3.2.0]heptane derivative of the formula III as (+)-(1S,5R,exo-6S) enantiomer:
in which R
1
has the abovementioned meaning, and converting the compound obtained in this way where appropriate into the acid addition salt of a physiologically tolerated acid.
Halogen atoms, in particular bromine or chlorine, are suitable and preferred as nucleofugic leaving group for Nu.
The reaction is expediently carried out in the presence of an inert base such as triethylamine or potassium carbonate as acid acceptor in an inert solvent such as a cyclic saturated ether, in particular tetrahydrofuran or dioxane, or a benzenoid hydrocarbon such as toluene or xylene.
The reaction is generally carried out at temperatures from 20 to 150° C., in particular from 80 to 1400C., and is generally complete within 1 to 10 hours.
The compounds of the formula I according to the invention can be either recrystallized by recrystallization [sic] from conventional organic solvents, preferably from a lower alcohol such as ethanol, or purified by column chromatography.
The free 3-azabicyclo[3.2.0]heptane derivatives of the formula I can be converted in a conventional way into the acid addition salt of a pharmacologically suitable acid, preferably by treating a solution with one equivalent of the appropriate acid. Examples of pharmaceutically suitable acids are hydrochloric acid, phosphoric acid, sulfuric acid, methanesulfonic acid, sulfamic acid, maleic acid, fumaric acid, oxalic acid, tartaric acid or citric acid.
The compounds according to the invention have valuable pharmacological properties. They can be used as neuroleptics (in particular atypical), antidepressants, sedatives, hypnotics, CNS protectives or agents for treating cocaine dependency. It is possible for several of the types of action mentioned to occur in combination in a compound according to the invention.
The substances are characterized in particular by a very high and selective affinity for dopamine D
4
and serotonin 2A receptors.
The prolongations of the QT interval measured on the model of the guinea pig capillary muscle are negligibly small. The novel substances are therefore well tolerated even at high dosages.
The invention accordingly also relates to a therapeutic composition having a content of a compound of the formula I or its pharmacologically suitable acid addition salt as active ingredient in addition to conventional carriers and diluents, and to the use of the novel compounds for controlling diseases.
The compounds according to the invention can be administered orally or parenterally, intravenously or intramuscularly, in a conventional way.
The dosage depends on the age, condition and weight of the patient and on the mode of administration. As a rule, the daily dose of active ingredient is between about 1 and 100 mg/kg of body weight on oral administration and between 0.1 and 10 mg/kg of body weight on parenteral administration.
The novel compounds can be used in conventional solid or liquid pharmaceutical forms, e.g. as uncoated or (film-)coated tablets, capsules, powders, granules, suppositories, solutions, ointments, creams or sprays. These are produced in a conventional way. The active ingredients can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, bulking agents, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, release-slowing agents, antioxidants and/or propellant gases (cf. H. Sucker et. al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). The administration forms obtained in this way normally contain the active ingredient in an amount of from 1 to 99% by weight.
The substances of the formula II and III required as starting materials for synthesizing the compounds according to the invention are known, (WO 94/00458; Heterocycles 40 (1), 319-330 (1995), Chimia 1990, 44, 120) or can be synthesized from analogous starting materials by preparation methods described in the literature.
REFERENCES:
patent: 94/00458 (1994-01-01), None
patent: 94/00431 (1994-01-01), None
patent: 95/15312 (1995-06-01), None
patent: 96/04245 (1996-02-01), None
patent: 96/04272 (1996-02-01), None
Pharm.Tech.Thieme Verlag, Stgt 1978, Sucker et al.
Heterocycles, vol. 40, No. 1, 1995, Steiner319-330.
Chima (May 1990), 44, 120-123, No. 5.
Hoger Thomas
Juchelka Frieder
Steiner Gerd
Teschendorf Hans-Jurgen
Unger Liliane
BASF - Aktiengesellschaft
Keil & Weinkauf
Stockton Laura L.
LandOfFree
N-substituted azabicycloheptane derivatives, production and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-substituted azabicycloheptane derivatives, production and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted azabicycloheptane derivatives, production and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2569624